Consensus is taking fax data, received by rural clinics, post acute, substance abuse clinics, home health et al, and helping them put it into their systems of records–which are in general not FHIR-enabled. They allow those facilities & services to receive referrals from acute care hospitals. By 2027 many of these standards are going to…
Recently, the Office of Management and Budget has released new procedures to assess government regulation (Circular A-4) and economic policies (Circular A-94). What is unique about this guidance is that it weights benefits and costs of new regulations and policies based on the income of the individuals impacted. The goal is to help reduce inequality….
When Anna Nusslock showed up at her local hospital 15 weeks pregnant and in severe pain earlier this year, she said, a doctor delivered devastating news: The twins she and her husband had so desperately wanted were not viable. Further, her own health was in danger, and she needed an emergency abortion to prevent hemorrhaging…
Sionna Therapeutics found strong investor interest in its cystic fibrosis drugs, which could rival blockbuster Vertex Pharmaceuticals product Trikafta. The biotech has three internally developed programs that hit a target unaddressed by any currently available CF therapies. The post Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline appeared first on…
It’s been a tumultuous past couple years for retail health companies —but there are still reasons to believe in the convenient model that retail health offers, said Annie Lamont, managing partner and co-founder of Oak HC/FT. The post Why One Investor Still Believes in Retail Health appeared first on MedCity News.
Pediatric innovation in mental health is the theme of the INVEST Digital Health Pitch Perfect contest at Pegasus Park in Dallas on September 18. The post Where is Pediatric Innovation Making an Impact? appeared first on MedCity News.
Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022. The post Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline appeared first on MedCity News.
Draft Continuing Resolution released on March 8 includes an extension of the telehealth flexibilities through September 30
Dr. Bhattacharya, a US COVID policy critic, has been nominated by Trump to lead the country’s top public funder of medical research
PEPFAR, the U.S. global HIV/AIDS program, is – for the first time in its two-decade history – facing significant challenges that could impede its ability to fulfill its mission. This policy brief provides an overview of recent events and ongoing challenges facing the program.